Cybin Inc. CYBN Archives - Page 15 of 18

TuesdaySep 14, 2021 9:42 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Likely to Benefit from New Research Touting Psilocybin Mental Health Treatments

Yale researchers publish study that a single dose of psilocybin counteracts symptoms of depression Administering drug to mice resulted in an approximately 10% increase in neuron size and density Cybin is focused on progressing psychedelic therapeutics As news of psychedelic research continues to report breakthroughs — such as the recent news from a group of Yale researchers that a single dose of psilocybin counteracts symptoms of depression (https://ibn.fm/NCORl) — companies operating in the space, including Cybin (NEO: CYBN) (NYSE American: CYBN), are ideally positioned to see significant benefits and growth. “Yale researchers found that a single dose of the naturally occurring psychedelic compound psilocybin…

ThursdaySep 09, 2021 1:07 pm

QualityStocksNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) CEO to Present Virtually at H.C. Wainwright 23rd Annual Global Investment Conference

Cybin (NEO: CYBN) (NYSE American: CYBN), a life sciences company focused on advancing psychedelic pharmaceutical therapeutics for various psychiatric and neurological conditions, today announced that on Monday, September 13, 2021, Chief Executive Officer Doug Drysdale will be presenting virtually at the H.C. Wainwright 23rd Annual Global Investment Conference. The presentation will be webcast on-demand beginning at 7:00 AM ET on September 13, and will be available for 90 days at https://ibn.fm/cWDdt To view the full press release, visit https://ibn.fm/2VJSS About Cybin Inc. Cybin is a leading biotechnology company focused on progressing psychedelic therapeutics by utilizing proprietary drug discovery platforms, innovative drug delivery…

FridaySep 03, 2021 11:59 am

QualityStocksNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Featured in Article as Stock That Is ‘Shaping up to Be a Brilliant Investment’

Cybin (NEO: CYBN) (NYSE American: CYBN), a life sciences company focused on advancing psychedelic pharmaceutical therapeutics for various psychiatric and neurological conditions, was highlighted in a Motley Fool article titled, “Buying Cybin Stock Right Now Could Be a Brilliant Move.” The piece, written by Alex Carchidi, delves into CYBN as one of those investment opportunities in places outside the mainstream. “Cybin (NYSE: CYBN) is a biotech that's developing mental illness treatments derived from widely illegal psychedelic chemicals like psilocybin (best known as the active compound in ‘magic mushrooms’). Based on a swath of extremely positive coverage in the scientific literature,…

WednesdaySep 01, 2021 9:55 am

QualityStocksNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Reports on Milestone Achievements Reached by Subsidiary

Cybin (NEO: CYBN) (NYSE American: CYBN), a biotechnology company focused on psychedelic pharmaceutical therapies, has announced that Adelia Therapeutics Inc., its wholly controlled subsidiary, has reached key milestones for Year 1 Q3. The milestones were outlined in last year’s transaction agreement between Cybin, Cybin Corp., Cybin US Holdings Inc. and previous shareholders of Adelia. Based on the agreement, 9,392.6 Class B common shares in the capital of Cybin will be issued to Adelia shareholders; the issuance is designed to satisfy the approximately $251,581.81 owed to the shareholders upon Adelia meeting the outlined milestones. The announcement noted that the Class B shares…

MondayAug 30, 2021 8:00 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Files Patent Applications to Support Research Phase Programs, Strengthen IP Portfolio

Company’s nonprovisional patent application includes claims to compositions, methods to support certain elements of preclinical and research programs Two international patent applications will grant Cybin the right to file future national applications into treaty member jurisdictions Cybin portfolio consists of 14 patent filings, 50-plus proprietary molecules, 50-plus preclinical studies and 4 active drug programs Cybin (NEO: CYBN) (NYSE American: CYBN), a biotechnology company focused on progressing psychedelic therapeutics, is moving forward to progress and strengthen its IP portfolio by filing three patents this month. After receiving an international search report of its May 2021 Patent Cooperation Treaty (“PCT”) application, Cybin…

FridayAug 27, 2021 11:02 am

QualityStocksNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Eyes Fueled Mission to Develop Revolutionary Psychedelic Therapeutics

Cybin (NEO: CYBN) (NYSE American: CYBN), a life sciences company advancing psychedelic therapeutics for various psychiatric and neurological conditions, in a recent historic move became the first psychedelic biotech company to trade on the NYSE American LLC stock exchange. “We are all delighted to receive this approval from the NYSE American and are thankful to our wonderful team and loyal investor base who have followed us on this journey so far,” an article quoted Cybin CEO Doug Drysdale discussing the milestone. “As the first psychedelic biotech company that will now trade on this esteemed exchange in the U.S., we will…

MondayAug 23, 2021 10:43 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Releases Q1 2021 Operational, Financial Report

Q1 2021 report notes distinction of becoming first psychedelic company to list on the NYSE American LLC stock exchange Cybin has garnered “a great deal of attention as an emerging leader in the psychedelic therapeutics space,” says CEO Several of the quarter’s highlights tied into the company’s active development of its psychedelic pipeline Cybin (NEO: CYBN) (NYSE American: CYBN) is wrapping up a highly successful first quarter with the release of its Q1 2021 operational and financial report, for the period ended June 30, 2021 (https://ibn.fm/V9xNp). The biotech company, which is focused on progressing psychedelic therapeutics, hit some milestones this quarter,…

ThursdayAug 19, 2021 11:14 am

Cybin Inc. (NEO: CYBN) (NYSE American CYBN) Adelia Acquisition Making Impact, Reaching Milestones

Cybin subsidiary achieved certain milestones as outlined in acquisition agreement Adelia brought numerous advantages to company Acquisition may advance “Cybin’s ability to innovate our psychedelic drug development program and diversify beyond major depressive disorder,” says CEO Cybin's (NEO: CYBN) (NYSE American CYBN) most recent acquisition, Adelia Therapeutics Inc., is already reporting success for the company (https://ibn.fm/ZtWL2). Cybin recently announced that the wholly controlled subsidiary had achieved certain milestones for the year as outlined in the acquisition agreement, resulting in Adelia shareholders receiving common shares in Cybin. Cybin closed on the acquisition of Adelia late last year, with the company noting…

ThursdayAug 19, 2021 9:30 am

QualityStocksNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American CYBN) Files Two International Patent Applications in Support of the Company’s Research Phase Programs

Cybin (NEO: CYBN) (NYSE American CYBN), a biotechnology company focused on progressing psychedelic therapeutics, has filed two additional international patent applications; these applications open the possibility for CYBN to obtain patent coverage in 153 countries and, if approved, allow the company to file future national applications into treaty member jurisdictions. The company filed the applications under the Patent Cooperation Treaty (“PCT”). One of the patent applications concerns a group of proprietary compounds that the company has identified as important for further evaluation toward selection as potential therapeutics. The other application regards claims and disclosures toward other proprietary novel psychedelic compounds, including…

TuesdayAug 17, 2021 10:40 am

QualityStocksNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American CYBN) Files 14th Patent Application, Announces New Board Member

Cybin (NEO: CYBN) (NYSE American CYBN), a biotechnology company focused on progressing psychedelic therapeutics, has filed a nonprovisional patent application in support of its ongoing drug candidate programs. The company noted that it had completed a favorable international search report regarding its May 2021 Patent Cooperation Treaty (“PCT”) application; as a result, it filed the U.S. nonprovisional application claiming priority to the May 2021 PCT application. The company noted that the International Patent Searching authority had written an opinion supporting novelty, inventive steps and industrial applicability to multiple claims within Cybin’s patent filing, including claims to compositions and methods that support…

Site Search

Company Search

Tag: Cybin Inc. CYBN